On May 14, Agilent Technologies (A) reported its second-quarter results. Its revenue rose 2.65% YoY (year-over-year) on a reported basis to $1.24 billion, missing analysts' estimate by $30.82 million.
On May 15, Immunogen (IMGN) issued a press release announcing the FDA’s recommendation to conduct a new Phase 3 trial.
On May 10, Puma Biotechnology (PBYI) reported its first-quarter results.
Insys Therapeutics (INSY) released its first-quarter earnings results on May 10.
Merck (MRK) closed at $78.19 on May 10, 0.18% below its previous close, 36.01% above its 52-week low of $57.49, and 6.75% below its 52-week high of $83.85.
Last week, cannabis ETFs fell for the second consecutive week.
Wall Street analysts expect an upside potential of 48.35% for Mylan based on the company’s closing price on May 7.
Chevron (CVX) has decided not to make a counteroffer to Anadarko Petroleum (APC) in response to Occidental Petroleum's (OXY) revised bid.
On May 8, Charlotte’s Web Holdings (CWEB) (CWBHF) released its preliminary first-quarter results after the markets closed.
On May 6, Bausch Health Companies (BHC) reported its first-quarter results. The company reported revenues of $2.02 billion in the first quarter.